With an aim to tap rapidly increasing clinical trials market in India, Oracle Health Sciences has launched Clinical One platform in the country. The cloud-based platform helps life science companies manage clinical trials in an efficient and effective way and introduce therapies to market in a faster and cost-effective way.
The Clinical One platform integrates clinical development operations and information in a single environment with shared functions and an easy-to-use interface for sites, clinical coordinators, and their counterparts. It also reduces the time to set up a clinical study.
James Streeter, global vice president, life sciences product strategy for Oracle Health Sciences, said “Over the years, India has been a leading exporter of generics to the global market. There are a number of generics companies coming up in other countries in a big way thus impacting India's market position in the segment. To remain competitive, Indian firms are now investing heavily in innovation & research and development of products. We will see more clinical trials being conducted by Indian companies in coming years.”
Traditionally, US and Europe were the hotspot for clinical trials. Now India and China are witnessing a rise in the number of clinical trials. Pharmaceutical companies are taking trials to the global level. They need solutions to integrate various clinical trial processes to ensure data safety and make the entire process faster and hassle-free, all at a reasonable cost. They are looking to bring efficiency in clinical trials and improve its quality in a cost-effective manner. Oracle's Clinical One platform has been designed to address such needs of life science firms, said Streeter.
The Clinical One offers a unified, cloud-based eClinical platform that enables companies to seamlessly share clinical trial data throughout all phases of the drug development lifecycle and across all functions, which is poised to take advantage of the expanding clinical market in India.
Over the last few years, the country has witnessed a slew of regulatory changes positioning its clinical trial industry on a growth trajectory, he added.
Talking about Clinical One platform, James said, “it is mainly for running clinical trials, randomizing subjects and trials, and they are made for the global market. They are very simple to set up, and it allows for vaccine trials to complex oncology trials. From simple to complex trials, it supports all these different types of trials from an input point of view”.
Yashi Kant, vice president, health sciences sales, Asia Pacific at Oracle Corporation says, “We do have vaccine trials running in India on our platform and it's being used like you would use it on any other trial. To facilitate randomizations, one has to have a certain amount of data pertaining to patients to see if they qualify for the trial. We also work on all the components that support clinical trials including systems that monitor sites and site performance, schedules, and events; and help with budgeting. Besides this, we have data capture and data safety modules in Clinical One platform.”